CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zydus Lifesciences Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zydus Lifesciences Ltd
Zydue Tower, Satellite Cross Road
Phone: +91 7926868100p:+91 7926868100 AHMEDABAD, 382481  India Ticker: ZYDUSLIFEZYDUSLIFE
Business Summary
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Pankaj R.Patel 71 7/12/2017 7/12/2017
Chief Financial Officer Nitin D.Parekh
Company Secretary, Chief Compliance Officer Dhaval N.Soni 2/7/2019 2/7/2019
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Sentynl Therapeutics, Inc. 420 Stevens Ave. Solana Beach CA United States
Zydus Animal Health and Investments Limited No. 63, Survey No. 536 , Zydus Corporate Park Ahmedabad Gujarat India
Nesher Pharmaceuticals (USA) LLC 13910 Saint Charles Rock Rd Bridgeton MO United States
Zydus Pharmaceuticals USA Inc. 73 Route 31 N Pennington NJ United States
Alidac Pharmaceuticals Limited Plot No.1A Pharnez SEZ India

Business Names
Business Name
532321
Alidac Healthcare (Myanmar) Limited
Alidac Pharmaceuticals Limited
53 additional Business Names available in full report.

General Information
Number of Employees: 26,240 (As of 3/31/2024)
Outstanding Shares: 1,006,233,990 (As of 9/30/2024)
Shareholders: 300,331
Stock Exchange: NSE
Fax Number: +91 7926862365


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024